Faculty

Jithma P. Abeykoon, M.D.

Clinical Studies

MC220806: Phase I Study Evaluating The Efficacy Of CSF1R And TAM Receptor Or Inhibition In Hematologic Malignancies With Q702, A Small Molecular Inhibitor Rochester, Minn., Scottsdale/Phoenix, Ariz. This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Phase 2 Trial Of Ulixertinib For Patients With Histiocytic Neoplasms Rochester, Minn.
The purpose of this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.

A Phase 1/2 Dose Evaluation Trial Of The Safety And Preliminary Efficacy Of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) In Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease Rochester, Minn. This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).